21 April 2026
21 April 2026
Lilly now has a lentiviral and LNP-based platform for in vivo delivery under its belt, which analyst Jack Cuthbertson says will give the company a broader chance for success.
The new site will focus on the use of AI models for purposes including the discovery and development of targeted medicines for patients with unmet medical needs.
Aicuris’ overall revenue is anticipated to reach $500m by 2030, not including AIC468.
British people are increasingly turning to potentially unregulated weight loss medications as drug prices climb and waits for prescriptions lengthen.
Non-GLP-1 obesity drugs are emerging, with this landscape expected to surge 50-fold over the next five years, generating $15.5bn in 2031.
Under the Prescription Drug User Fee Act, the FDA has set a target action date of 17 August 2026.
In this issue: CDMOs use of digital twins to realise a strategic advantage, Physical AI's rise in pharma manufacturing, and more.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
